Roche’s multiple sclerosis pill more than doubled patients’ relapse-free interval compared with Sanofi’s marketed MS pill Aubagio, according to data presented late on Tuesday.
The drug, a BTK inhibitor called fenebrutinib, demonstrated “the lowest relapse ...
↧